EFFICACY & SFTY OF SHRT CORSE ANTIRETROVIRAL THRPY FOR ACUTE OR RECNT HIV-1 INF

功效

• 批准号: 7604491
• 负责人: MICHELLE A. BARRON
• 金额: $ 1.24万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604491
• 关键词: Acute; Adverse effects; Anti-HIV Agents; Anti-Retroviral Agents; Blood; Chronic; Computer Retrieval of Information on Scientific Projects Database; Drug usage; Funding; Grant; HIV; HIV Infections; Immune system; Institution; Learning; Lopinavir; Lopinavir/Ritonavir; Medicine; Pharmaceutical Preparations; Research; Research Personnel; Resources; Ritonavir; Source; Tenofovir; Time; United States Food and Drug Administration; United States National Institutes of Health; Viral Load result; Virus; improved; truvada

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to learn if treating people during early HIV infection is beneficial. In other words, this study will evaluate how safe and effective a combination of anti-HIV drugs (emcitrabine plus tenofovir (Truvada) and lopinavir plus ritonavir (Kaletra) is for people with recently acquired HIV infection. It is known that combination anti-HIV drugs decreases the amount of virus in the blood (viral load) and improve the immune system. However, these drugs also have short-term and long-term side effects that are also considered when people decide whether or not to begin anti-HIV medicine. The opinions of HIV treatment experts regarding when to start anti-HIV medicine do change as we learn more about the anti-HIV drugs and their good and bad effects over time. The three drugs used in this study have been approved of by the U.S. Food and Drug Administration for the treatment of people with chronic HIV infection.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项研究的目的是了解治疗早期艾滋病毒感染者是否有益。换句话说，这项研究将评估抗 HIV 药物组合（恩西曲滨加替诺福韦（Truvada）和洛匹那韦加利托那韦（Kaletra）对于最近感染 HIV 的人的安全性和有效性。众所周知，联合抗 HIV 药物可以减少血液中的病毒量（病毒载量）并改善免疫系统。但是，这些药物也有短期和长期的作用。 当人们决定是否开始抗艾滋病毒药物时也会考虑副作用。随着我们对抗艾滋病毒药物及其随着时间的推移的好坏影响了解得更多，艾滋病毒治疗专家关于何时开始抗艾滋病毒药物的观点确实发生了变化。本研究中使用的三种药物已获得美国食品和药物管理局批准用于治疗慢性艾滋病毒感染者。